Similar safety and efficacy of once-and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 2, 2010, Pages 143-151

  Zajdenverg, Roberto ^a   Podsadecki, Thomas J ^b   Badal Faesen, Sharlaa ^c   Andrade Villanueva, Jaime ^c   Gathe, Joseph ^d   Mingrone, Horacio ^e   Fredrick, Linda M ^b   Gaultier, Isabelle A ^b   Woodward, W Chris ^b   Bernstein, Barry M ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b University of Witwatersrand ^*

^c HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^d Hospital Muñiz   (Argentina)

^e HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

Highly active antiretroviral therapy; HIV protease inhibitors; HIV 1; Once daily; Treatment experienced

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALGORITHM; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NAUSEA; PYRIMIDINONES; RITONAVIR; VIRAL LOAD; YOUNG ADULT;

EID: 77953047639     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181cbd21e     Document Type: Article

References (24)

1. Lohse N, Hansen A-BE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2008; 146:87-95.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
3. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
4. Boyle BA, Jayaweera D, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9:164-176.
5. Molina J-M. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68:567-578.
6. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48: 484-488.
7. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505-1514.
8. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50:474-481.
9. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
10. Gonzalez-Garcia J, Cohen DE, Johnson M, et al. Comparable safety and efficacy with once-daily (QD) versus twice-daily (BID) dosing of lopinavir/ritonavir (LPV/r) tablets with emtricitabine (FTC) + tenofovir DF (TDF) in antiretroviral (ARV)-naïve, HIV-1-infected subjects: 96 week results of the randomized trial M05-730 [MOPEB035]. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
11. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of infection. N Engl J Med. 2002;346: 2039-2046.
12. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75: 7462-7469.
13. Mo H, King MS, King K, et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir-ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005;79:3329-3338.
14. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2003;37:113-128.
15. King MS, Rode R, Cohen-Codar I, et al. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2007;51:3067-3074.
16. Abbott Laboratories. Kaletra Tablets and Oral Solution, Full Prescribing Information. Abbott Laboratories, October 2008. Available at: http:// www.rxabbott.com/pdf/kaletratabpi.pdf. Accessed April 13, 2009.
17. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
18. Rode R, Vrijens B, Niemi K, et al. Differences in treatment compliance between lopinavir/ritonavir (LPV/r) given once (QD) versus twice (BID) daily do not affect virologic or immunologic outcomes [H-522]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemo-therapy (ICAAC); December 16-19, 2005; Washington, DC.
19. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16:138-145.
20. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA panel. JAMA. 1998;279:1984-1991.
21. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47: 266-285.
22. Elston R, Yates P, Tisdale M, et al. GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype [MoOrB1055]. Presented at: The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
23. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
24. de Mendoza C, Valer L, Ribera E, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials. 2006;7: 163-171.